MarketCap
Facebook
X
TelegramAnnual report 2026
added 02-10-2026
Exelixis Accounts Receivables 2011-2026 | EXEL
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Exelixis
| 2026 | 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 287 M | 265 M | 237 M | 215 M | 283 M | 119 M | - | 163 M | 77.3 M | 42.2 M | 5.18 M | 4.88 M | 3.94 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 287 M | 3.94 M | 142 M |
Quarterly Accounts Receivables Exelixis
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 310 M | 292 M | 282 M | 265 M | 270 M | 397 M | 241 M | 237 M | 248 M | 233 M | 234 M | 215 M | 215 M | 235 M | 191 M | 283 M | 179 M | 172 M | 178 M | 119 M | 166 M | 121 M | 137 M | - | 170 M | 97.5 M | 108 M | 163 M | 163 M | 163 M | 163 M | 11.6 M | 88.9 M | 81.2 M | 81.2 M | 40.4 M | 91.2 M | 40.4 M | 40.4 M | 5.18 M | 5.18 M | 5.18 M | 5.18 M | 4.88 M | 4.88 M | 4.88 M | 4.88 M | 3.94 M | 3.94 M | 3.94 M | 3.94 M | 2.75 M | 2.75 M | 2.75 M | 2.75 M | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 397 M | 2.75 M | 126 M |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Heron Therapeutics
HRTX
|
89.6 M | $ 0.8 | 2.7 % | $ 133 M |  USA |
 |
Amphastar Pharmaceuticals
AMPH
|
144 M | $ 19.23 | -1.38 % | $ 899 M | USA |
 |
Altimmune
ALT
|
1.22 M | $ 3.44 | 2.99 % | $ 303 M | USA |
 |
Aytu BioScience
AYTU
|
31.2 M | $ 2.63 | 0.77 % | $ 16.5 M | USA |
 |
I-Mab
IMAB
|
130 M | - | - | $ 866 M |  China |
 |
Incyte Corporation
INCY
|
1.02 B | $ 90.45 | -0.36 % | $ 17.7 B | USA |
 |
Inovio Pharmaceuticals
INO
|
18.6 M | $ 1.61 | 1.9 % | $ 35.7 M | USA |
 |
AgeX Therapeutics
AGE
|
57 K | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
17.3 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
3.27 M | - | -0.23 % | $ 916 M | USA |
 |
Acasti Pharma
ACST
|
802 K | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
886 K | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
234 K | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
234 K | - | - | $ 7.46 M |  Israel |
 |
BioDelivery Sciences International
BDSI
|
56.9 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
865 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
1.54 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
2.76 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
411 K | - | - | $ 3.74 B | USA |
 |
Karyopharm Therapeutics
KPTI
|
30.8 M | $ 6.66 | -12.71 % | $ 812 K | USA |
 |
Keros Therapeutics
KROS
|
3.57 M | $ 11.24 | 2.55 % | $ 418 M | USA |
 |
Clovis Oncology
CLVS
|
26.9 M | - | -7.23 % | $ 13 M | USA |
 |
Longeveron
LGVN
|
104 K | $ 0.95 | -2.71 % | $ 16.7 B | USA |
 |
Denali Therapeutics
DNLI
|
2.17 M | $ 21.09 | 4.56 % | $ 3.47 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
1.78 M | $ 4.42 | 4.25 % | $ 734 M | Canada |